Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation reports news on its Omnipod product platform for diabetes care, including the Omnipod Insulin Management System and Omnipod 5 Automated Insulin Delivery System. The company’s tubeless disposable Pods provide up to three days of insulin delivery, while Omnipod 5 integrates with continuous glucose monitors and can be controlled through a compatible smartphone in the U.S. or through the Omnipod 5 Controller.
Recurring Insulet developments include quarterly results, Omnipod revenue trends, sensor-connectivity updates, clinical evidence for automated insulin delivery, and research involving fully closed-loop systems for type 2 diabetes. Company updates also cover medical device corrections, product quality actions, executive appointments, conference presentations, and the use of Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet (NASDAQ:PODD) will showcase new Omnipod data and innovations at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Highlights include next‑generation AID algorithms, STRIVE and EVOLUTION 3 study data, Omnipod Discover™, and multiple oral, poster, and theater presentations.
Insulet (NASDAQ:PODD) announced the U.S. rollout of an enhanced Omnipod 5 automated insulin delivery algorithm, cleared via FDA 510(k) in December 2025, plus compatibility with Abbott’s Libre 3 Plus sensor.
Updates add a new 100 mg/dL Target Glucose option, more personalization, improved alarm handling, and expanded sensor choice.
Insulet (NASDAQ:PODD) will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. CT. A live webcast and replay will be available on the Insulet investor relations website.
Insulet (NASDAQ:PODD) announced a voluntary Medical Device Correction for certain lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods in the U.S. and some international markets due to a manufacturing issue that may cause insulin under-delivery.
About 7 million Pods are affected, representing roughly 8.5% of 2025 global Pod production. Approximately 60% of these Pods are already consumed or expired. There have been 24 reports of serious adverse events related to high blood glucose and diabetic ketoacidosis, with no deaths. Insulet reports it has identified the cause, implemented corrective actions, strengthened quality controls, and is offering free replacement Pods, with no expected supply disruption.
Insulet (NASDAQ: PODD) reported Q1 2026 revenue of $761.7 million, up 33.9% (30.1% constant currency). Total Omnipod revenue was $758.4 million. GAAP net income was $91.1 million ($1.30 diluted EPS); adjusted net income was $99.8 million ($1.42 adjusted EPS).
The company raised full‑year revenue guidance, noted margin expansion, launched Omnipod 5/Discover in five Middle East countries, advanced AID clinical programs, repurchased 1.25 million shares, and provided Q2 and FY 2026 constant‑currency guidance.
Insulet (NASDAQ: PODD) published its 2025 Sustainability Report highlighting progress across operations, products, people, and community. Key metrics: 13% of global electricity from renewables, 24% Malaysia site on onsite solar, 8.9 million Pods accepted, and 23% reduction in baseline packaging weight. The report also expands U.S. Pod recycling to all 50 states and DC and reports 2,900+ employee volunteer hours through Insulet for Good.
Insulet (NASDAQ: PODD) enrolled the first participant in the EVOLVE pivotal randomized control trial of a fully closed-loop automated insulin delivery (FCL AID) system for type 2 diabetes. The multi-center U.S. study may enroll up to 350 adults and follows FDA IDE approval in March 2026.
Insulet reported prior feasibility and SECURE-T2D results showing improved time-in-range and lower HbA1c, and plans a 510(k) filing in 2027 with an expected launch in 2028.
Insulet (NASDAQ: PODD) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. PT. A live webcast and replay will be available on the Insulet investor relations website.
The presentation covers company updates and the Omnipod product platform; webcast access: investors.insulet.com/events.
Insulet (NASDAQ: PODD) announced it will report first quarter 2026 financial results on Wednesday, May 6, 2026, before the opening of U.S. markets. Management will host a conference call at 8:00 a.m. Eastern Time that day and a live webcast will be available.
Investors can join via the Investor Relations "Events and Presentations" page, or by dialing the provided domestic and international numbers using passcode 5904836. The webcast will be archived for future replay. The company markets the Omnipod tubeless insulin pump platform and Omnipod 5 automated insulin delivery system.
Insulet (NASDAQ: PODD) appointed Mike Panos as Executive Vice President, Chief Commercial Officer, effective March 30, 2026. Mr. Panos will lead the company’s global commercial organization and report to President and CEO Ashley McEvoy as a member of the Executive Leadership Team.
He brings 30 years of medical-technology commercial leadership, most recently at Stryker, and will focus on commercial strategy, market access, and expansion into new patient populations and care settings to support growth of the Omnipod platform.